BreezeBio (formerly GenEdit)

BreezeBio, Inc. (formerly GenEdit) is a clinical-stage genetic medicines company based in South San Francisco, California, solving the central delivery problem of gene editing and genetic medicine. Its proprietary NanoGalaxy platform is a library of thousands of non-viral, non-lipid polymer nanoparticles engineered to deliver genetic payloads (mRNA, DNA, and CRISPR ribonucleoprotein) to specific cell types and tissues without triggering an immune response. The company is advancing an internal pipeline of precision genetic medicines focused on autoimmune disease and oncology, led by BRZ-101, a tolerance-inducing candidate for Type 1 diabetes. GenEdit rebranded to BreezeBio in February 2026 alongside a $60M Series B, and has established platform partnerships with Roche's Genentech and Sarepta Therapeutics. This is a therapeutics company with no public developer API, SDK, or developer portal; the profile captures its identity and domain-security posture.

BreezeBio (formerly GenEdit) is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Genetic Medicine, Gene Editing, and Drug Delivery.

BreezeBio (formerly GenEdit)’s developer surface includes engineering blog, support, and 6 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyGenetic MedicineGene EditingDrug DeliveryNanoparticlesCRISPRTherapeuticsLife SciencesHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 11.9/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/geneditbio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 5

The organization behind the API

Website

Website

Blog

Careers

LinkedIn

Source (apis.yml)

aid: geneditbio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/geneditbio.png
name: BreezeBio (formerly GenEdit)
description: BreezeBio, Inc. (formerly GenEdit) is a clinical-stage genetic medicines company based in South San Francisco,
  California, solving the central delivery problem of gene editing and genetic medicine. Its proprietary NanoGalaxy platform
  is a library of thousands of non-viral, non-lipid polymer nanoparticles engineered to deliver genetic payloads (mRNA, DNA,
  and CRISPR ribonucleoprotein) to specific cell types and tissues without triggering an immune response. The company is advancing
  an internal pipeline of precision genetic medicines focused on autoimmune disease and oncology, led by BRZ-101, a tolerance-inducing
  candidate for Type 1 diabetes. GenEdit rebranded to BreezeBio in February 2026 alongside a $60M Series B, and has established
  platform partnerships with Roche's Genentech and Sarepta Therapeutics. This is a therapeutics company with no public developer
  API, SDK, or developer portal; the profile captures its identity and domain-security posture.
url: https://raw.githubusercontent.com/api-evangelist/geneditbio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
x-rebranded-to: BreezeBio
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Genetic Medicine
- Gene Editing
- Drug Delivery
- Nanoparticles
- CRISPR
- Therapeutics
- Life Sciences
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://breezebio.com
- type: Website
  name: Legacy domain (GenEdit)
  url: https://geneditbio.com
- type: Blog
  name: News
  url: https://breezebio.com/news/
- type: Support
  name: Contact
  url: https://breezebio.com/contact/
- type: PrivacyPolicy
  url: https://breezebio.com/privacy-policy/
- type: Careers
  url: https://breezebio.com/careers/
- type: LinkedIn
  url: https://www.linkedin.com/company/genedit
- type: DomainSecurity
  url: security/geneditbio-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence